The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Frequency and oncologic outcomes of KRAS mutations in circulating tumor DNA of patients with pancreatic ductal adenocarcinoma.
 
Mahmoud M.G. Yousef
No Relationships to Disclose
 
Mark W. Hurd
No Relationships to Disclose
 
Abdelrahman M.G. Yousef
No Relationships to Disclose
 
Rebecca A Snyder
No Relationships to Disclose
 
Mark Knafl
No Relationships to Disclose
 
Mohammad Mahdi Fanaeian
No Relationships to Disclose
 
Ray Chacko
No Relationships to Disclose
 
Jennifer Peterson
No Relationships to Disclose
 
Brandon George Smaglo
Consulting or Advisory Role - Ipsen; Syros Pharmaceuticals
Research Funding - AstraZeneca; Merck
Travel, Accommodations, Expenses - Marker Therapeutics
(OPTIONAL) Uncompensated Relationships - Ipsen
 
Robert A. Wolff
Honoraria - Conveners; Emirates Oncology Society
Patents, Royalties, Other Intellectual Property - Royalties from McGraw-Hill: Editor: M.D. Anderson Manual of Medical Oncology, 3rd edition.
 
Shubham Pant
Consulting or Advisory Role - AskGene Pharma; Boehringer Ingelheim; Ipsen; Janssen; Novartis; Zymeworks
Research Funding - 4D Pharma (Inst); Amal Therapeutics (Inst); Arcus Biosciences (Inst); Astellas Pharma (Inst); bionte (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Elicio Therapeutics (Inst); Immuneering (Inst); ImmunoMET (Inst); Ipsen (Inst); Janssen (Inst); Lilly (Inst); Mirati Therapeutics (Inst); NGM Biopharmaceuticals (Inst); Novartis (Inst); Pfizer (Inst); Purple Biotech (Inst); Rgenix (Inst); Xencor (Inst); Zymeworks (Inst)
 
Michael Sangmin Lee
Consulting or Advisory Role - Bayer Health; Delcath Systems; G1 Therapeutics; Imvax; Pfizer
Research Funding - Arcus Biosciences (Inst); Boehringer Ingelheim (Inst); EpimAb BioTherapeutics (Inst); Erasca, Inc (Inst); Merck (Inst); Repare Therapeutics (Inst); TriSalus Life Sciences (Inst); Xilis (Inst)
 
Michael J. Overman
Consulting or Advisory Role - 3D Medicines; Array BioPharma; Bristol-Myers Squibb; Eisai; Gritstone Bio; Janssen; Janssen; MedImmune; Merck; Novartis; Pfizer; Pfizer; Promega; Roche/Genentech; Spectrum Pharmaceuticals
Research Funding - Bristol-Myers Squibb; MedImmune; Merck; Roche
 
Ching-Wei D. Tzeng
Honoraria - PanTher Therapeutics
Research Funding - Sirtex Medical (Inst)
 
Matthew H. G. Katz
Consulting or Advisory Role - Abbvie; Abbvie; Abbvie; Alcresta Therapeutics; Nestle health science; Taiho Oncology
Travel, Accommodations, Expenses - Intuitive Surgical
 
Huamin Wang
No Relationships to Disclose
 
Anirban Maitra
Consulting or Advisory Role - Freenome; Tezcat Biosciences
Patents, Royalties, Other Intellectual Property - Johns Hopkins University has licensed a patent related to pancreatic cancer to Thrive Earlier Detection. I have 1.8% contribution on that patent.; PCT/US2017/066851 (Inst)
 
Ethan B. Ludmir
Employment - Alaunos Therapeutics (I)
 
John Paul Y.C. Shen
Stock and Other Ownership Interests - Agios; Syndax; Syndax
Consulting or Advisory Role - Engine Biosciences
Research Funding - BostonGene; Celsius Therapeutics; Celsius Therapeutics
 
Dan Zhao
Consulting or Advisory Role - Affinit-T
Research Funding - CARsgen Therapeutics (Inst); Mirati Therapeutics (Inst)